Alnylam Pharmaceuticals, Inc. (ALNY) Misses Q2 EPS by 7c
Get Alerts ALNY Hot Sheet
Price: $143.80 -1.55%
Revenue Growth %: +33.0%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
NLY, CP, RUSHA, More
Revenue Growth %: +33.0%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
NLY, CP, RUSHA, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q2 EPS of ($0.63), $0.07 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $9.36 million.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
- Teradyne (TER) Tops Q1 EPS by 18c
- Methanex (MEOH) Tops Q1 EPS by 35c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!